Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

Just got this alert;

ADXS: Analyst Mara Goldstein reiterated a Buy rating on Advaxis.

Goldstein observed;

Multiple Clinical Milestones, AIM2CERV Timeline. AIM2CERV, a Phase III trial in high-risk, locally advanced cervical cancer, is under way and is to enroll 400+ patients globally, likely by the end of 2018, with completion expected in 2020. FAWCETT, a Phase II trial, is under way, and Stage 1 data from the trial are to be presented at ESMO (9/17), with a pivotal trial in sight in 2018.”